Role of innate immunity in neonatal infection

American Journal of Perinatology

Volumn 30, Issue 2, 2013, Pages 105-112

  Cuenca, Alex G ^a   Wynn, James L ^b   Moldawer, Lyle L ^a   Levy, Ofer ^c,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adjuvants; innate immunity; neonatal sepsis; pathogen recognition receptors

Indexed keywords

ACTIVATED PROTEIN C; ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COMPLEMENT; CYCLIC AMP; DEFENSIN; GAMMA INTERFERON; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; IMIDAZOQUINOLINE DERIVATIVE; IMMUNOGLOBULIN; INFLAMMASOME; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1BETA; LACTOFERRIN; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; PERTUSSIS VACCINE; PHOSPHORYL LIPID A; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SURFACTANT PROTEIN A; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; B LYMPHOCYTE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFICACY; EFFECTOR CELL; ESCHERICHIA COLI; GENETIC POLYMORPHISM; HAEMOPHILUS INFLUENZAE; HEPATITIS B; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION SENSITIVITY; INFLUENZA; INNATE IMMUNITY; LOW BIRTH WEIGHT; MENINGOCOCCEMIA; MYCOBACTERIOSIS; NECROTIZING ENTEROCOLITIS; NEWBORN INFECTION; NEWBORN SEPSIS; NONHUMAN; PERITONITIS; PERTUSSIS; PHAGOLYSOSOME; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PREMATURITY; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION; VERTICAL TRANSMISSION;

ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; BLOOD PROTEINS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFANT, NEWBORN; INFLAMMASOMES; LACTOFERRIN; LECTINS, C-TYPE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 84874110756     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0032-1333412     Document Type: Article

References (91)

1. Lawn J. E., Cousens S., Zupan J. Lancet Neonatal Survival Steering Team 4 million neonatal deaths: when? Where? Why? Lancet: 2005; 365 891 900
2. Sanchez-Schmitz G., Levy O. Development of newborn and infant vaccines. Sci Transl Med: 2011; 3 90ps27
3. Lukacs S. L., Schoendorf K. C., Schuchat A. Trends in sepsis-related neonatal mortality in the United States, 1985-1998. Pediatr Infect Dis J: 2004; 23 599 603
4. Wynn J. L., Wong H. R. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol: 2010; 37 439 479
5. PrabhuDas M., Adkins B., Gans H., et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol: 2011; 12 189 194
6. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity: 2011; 34 637 650
7. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol: 2007; 7 379 390
8. Adkins B., Leclerc C., Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol: 2004; 4 553 564
9. Zhu J., Paul W. E. CD4 T cells: fates, functions, and faults. Blood: 2008; 112 1557 1569
10. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol: 2007; 7 179 190
11. Wynn J. L., Scumpia P. O., Delano M. J., et al. Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock: 2007; 28 675 683
12. Canaday D. H., Chakravarti S., Srivastava T., et al. Class II MHC antigen presentation defect in neonatal monocytes is not correlated with decreased MHC-II expression. Cell Immunol: 2006; 243 96 106
13. Adkins B., Bu Y., Cepero E., Perez R. Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates. J Immunol: 2000; 164 2347 2353
14. Adkins B., Bu Y., Guevara P. Murine neonatal CD4+ lymph node cells are highly deficient in the development of antigen-specific Th1 function in adoptive adult hosts. J Immunol: 2002; 169 4998 5004
15. Rose S., Lichtenheld M., Foote M. R., Adkins B. Murine neonatal CD4+ cells are poised for rapid Th2 effector-like function. J Immunol: 2007; 178 2667 2678
16. Duthie M. S., Windish H. P., Fox C. B., Reed S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev: 2011; 239 178 196
17. Zaghouani H., Hoeman C. M., Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol: 2009; 30 585 591
18. Yost C. C., Cody M. J., Harris E. S., et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood: 2009; 113 6419 6427
19. Wynn J. L., Scumpia P. O., Winfield R. D., et al. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood: 2008; 112 1750 1758
20. Gessler P., Nebe T., Birle A., Haas N., Kachel W. Neutrophil respiratory burst in term and preterm neonates without signs of infection and in those with increased levels of C-reactive protein. Pediatr Res: 1996; 39 843 848
21. Sadeghi K., Berger A., Langgartner M., et al. Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. J Infect Dis: 2007; 195 296 302
22. Yan S. R., Qing G., Byers D. M., Stadnyk A. W., Al-Hertani W., Bortolussi R. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect Immun: 2004; 72 1223 1229
23. Forsthuber T., Yip H. C., Lehmann P. V. Induction of TH1 and TH2 immunity in neonatal mice. Science: 1996; 271 1728 1730
24. Yip H. C., Karulin A. Y., Tary-Lehmann M., et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol: 1999; 162 3942 3949
25. Aksoy E., Albarani V., Nguyen M., et al. Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood: 2007; 109 2887 2893
26. De Wit D., Tonon S., Olislagers V., et al. Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J Autoimmun: 2003; 21 277 281
27. Vanden Eijnden S., Goriely S., De Wit D., Goldman M., Willems F. Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns. Eur J Immunol: 2006; 36 21 26
28. Picard C., von Bernuth H., Ghandil P., et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore): 2010; 89 403 425
29. Provenzano R. W., Wetterlow L. H., Sullivan C. L. Immunization and antibody response in the newborn infant. I. Pertussis inoculation within twenty-four hours of birth. N Engl J Med: 1965; 273 959 965
30. Wood N., McIntyre P., Marshall H., Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J: 2010; 29 209 215
31. Tarnow-Mordi W., Isaacs D., Dutta S. Adjunctive immunologic interventions in neonatal sepsis. Clin Perinatol: 2010; 37 481 499
32. Carr R., Brocklehurst P., Doré C. J., Modi N. Granulocyte- macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet: 2009; 373 226 233
33. Decembrino L., D'Angelo A., Manzato F., et al. Protein C concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: a pilot study. Shock: 2010; 34 341 345
34. Wynn J. L., Seed P. C., Cotten C. M. Does IVIg administration yield improved immune function in very premature neonates? J Perinatol: 2010; 30 635 642
35. Sgro M., Shah P. S., Campbell D., Tenuta A., Shivananda S., Lee S. K. Canadian Neonatal Network Early-onset neonatal sepsis: rate and organism pattern between 2003 and 2008. J Perinatol: 2011; 31 794 798
36. van den Hoogen A., Gerards L. J., Verboon-Maciolek M. A., Fleer A., Krediet T. G. Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents. Neonatology: 2010; 97 22 28
37. Hornik C. P., Fort P., Clark R. H., et al. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum Dev: 2012; 88 02 S69 S74
38. Vosters O., Lombard C., André F., Sana G., Sokal E. M., Smets F. The interferon-alpha and interleukin-10 responses in neonates differ from adults, and their production remains partial throughout the first 18 months of life. Clin Exp Immunol: 2010; 162 494 499
39. Maródi L. Neonatal innate immunity to infectious agents. Infect Immun: 2006; 74 1999 2006
40. Maródi L. Innate cellular immune responses in newborns. Clin Immunol: 2006; 118 137 144
41. Carr R. Neutrophil production and function in newborn infants. Br J Haematol: 2000; 110 18 28
42. Chassin C., Kocur M., Pott J., et al. miR-146a mediates protective innate immune tolerance in the neonate intestine. Cell Host Microbe: 2010; 8 358 368
43. Belderbos M. E., van Bleek G. M., Levy O., et al. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin Immunol: 2009; 133 228 237
44. Chelvarajan L., Popa D., Liu Y., Getchell T. V., Stromberg A. J., Bondada S. Molecular mechanisms underlying anti-inflammatory phenotype of neonatal splenic macrophages. J Leukoc Biol: 2007; 82 403 416
45. Nahid M. A., Satoh M., Chan E. K. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol: 2011; 186 1723 1734
46. Nahid M. A., Pauley K. M., Satoh M., Chan E. K. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem: 2009; 284 34590 34599
47. Lederhuber H., Baer K., Altiok I., Sadeghi K., Herkner K. R., Kasper D. C. MicroRNA-146: tiny player in neonatal innate immunity? Neonatology: 2011; 99 51 56
48. Power Coombs M. R., Belderbos M. E., Gallington L. C., Bont L., Levy O. Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev Anti Infect Ther: 2011; 9 261 269
49. Levy O., Coughlin M., Cronstein B. N., Roy R. M., Desai A., Wessels M. R. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol: 2006; 177 1956 1966
50. Philbin V. J., Dowling D. J., Gallington L. C., et al. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol: 2012; 130 195 204, e9
51. Belderbos M. E., Levy O., Stalpers F., Kimpen J. L., Meyaard L., Bont L. Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. PLoS ONE: 2012; 7 e33419
52. Levy O. A Pediatric Perspective on Antimicrobial Proteins and Peptides: Expression, Function, and Clinical Relevance. London, UK Horizon Scientific Press: 2004; 305 329
53. Philbin V. J., Levy O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities. Biochem Soc Trans: 2007; 35 Pt 6 1485 1491
54. Bouma G., Doffinger R., Patel S. Y., et al. Impaired neutrophil migration and phagocytosis in IRAK-4 deficiency. Br J Haematol: 2009; 147 153 156
55. Orange J. S., Jain A., Ballas Z. K., Schneider L. C., Geha R. S., Bonilla F. A. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol: 2004; 113 725 733
56. Hoebe K., Janssen E. M., Kim S. O., et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol: 2003; 4 1223 1229
57. Kollmann T. R., Levy O., Montgomery R. R., Goriely S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity: 2012; 37 771 783
58. Corbett N. P., Blimkie D., Ho K. C., et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS ONE: 2010; 5 e15041
59. Burl S., Townend J., Njie-Jobe J., et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS ONE: 2011; 6 e18185
60. Netea M. G., Quintin J., van der Meer J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe: 2011; 9 355 361
61. Aaby P., Roth A., Ravn H., et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis: 2011; 204 245 252
62. Auriti C., Prencipe G., Inglese R., et al. Role of mannose-binding lectin in nosocomial sepsis in critically ill neonates. Hum Immunol: 2010; 71 1084 1088
63. Frakking F. N., Brouwer N., Zweers D., et al. High prevalence of mannose-binding lectin (MBL) deficiency in premature neonates. Clin Exp Immunol: 2006; 145 5 12
64. Frakking F. N., Brouwer N., van Eijkelenburg N. K., et al. Low mannose-binding lectin (MBL) levels in neonates with pneumonia and sepsis. Clin Exp Immunol: 2007; 150 255 262
65. Dzwonek A. B., Neth O. W., Thiébaut R., et al. The role of mannose-binding lectin in susceptibility to infection in preterm neonates. Pediatr Res: 2008; 63 680 685
66. Szala A., Paradowska E., Nowakowska D., et al. Mannan-binding lectin-2 (MBL2) gene polymorphisms in prenatal and perinatal cytomegalovirus infections. Mol Immunol: 2011; 48 2203 2206
67. van der Zwet W. C., Catsburg A., van Elburg R. M., Savelkoul P. H., Vandenbroucke-Grauls C. M. Mannose-binding lectin (MBL) genotype in relation to risk of nosocomial infection in pre-term neonates in the neonatal intensive care unit. Clin Microbiol Infect: 2008; 14 130 135
68. Awasthi S., Brown K., King C., Awasthi V., Bondugula R. A toll-like receptor-4-interacting surfactant protein-A-derived peptide suppresses tumor necrosis factor-α release from mouse JAWS II dendritic cells. J Pharmacol Exp Ther: 2011; 336 672 681
69. Awasthi S., Madhusoodhanan R., Wolf R. Surfactant protein-A and toll-like receptor-4 modulate immune functions of preterm baboon lung dendritic cell precursor cells. Cell Immunol: 2011; 268 87 96
70. Manzoni P., Rinaldi M., Cattani S., et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA: 2009; 302 1421 1428
71. Venkatesh M. P., Abrams S. A. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev: 2010; 5 CD007137
72. Krasity B. C., Troll J. V., Weiss J. P., McFall-Ngai M. J. LBP/BPI proteins and their relatives: conservation over evolution and roles in mutualism. Biochem Soc Trans: 2011; 39 1039 1044
73. Canny G., Levy O., Furuta G. T., et al. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A: 2002; 99 3902 3907
74. Canny G., Cario E., Lennartsson A., et al. Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am J Physiol Gastrointest Liver Physiol: 2006; 290 G557 G567
75. Levy O., Martin S., Eichenwald E., et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability- increasing protein. Pediatrics: 1999; 104 1327 1333
76. Michalek J., Svetlikova P., Fedora M., et al. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med: 2007; 33 2158 2164
77. Levin M., Quint P. A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet: 2000; 356 961 967
78. Guinan E. C., Barbon C. M., Kalish L. A., et al. Bactericidal/ permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med: 2011; 3 ra118
79. Palmer C. D., Guinan E. C., Levy O. Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. Biochem Soc Trans: 2011; 39 994 999
80. Richter M., Topf H. G., Gröschl M., et al. Influence of gestational age, cesarean section, and type of feeding on fecal human beta-defensin 2 and tumor necrosis factor-alpha. J Pediatr Gastroenterol Nutr: 2010; 51 103 105
81. Shim D. H., Ryu S., Kweon M. N. Defensins play a crucial role in protecting mice against oral Shigella flexneri infection. Biochem Biophys Res Commun: 2010; 401 554 560
82. Ricci E., Malacrida S., Zanchetta M., Montagna M., Giaquinto C., De Rossi A. Role of beta-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr: 2009; 51 13 19
83. Rapista A., Ding J., Benito B., et al. Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology: 2011; 8 45
84. Skeldon A., Saleh M. The inflammasomes: molecular effectors of host resistance against bacterial, viral, parasitic, and fungal infections. Front Microbiol: 2011; 2 15
85. Kanneganti T. D. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol: 2010; 10 688 698
86. Gotsch F., Romero R., Chaiworapongsa T., et al. Evidence of the involvement of caspase-1 under physiologic and pathologic cellular stress during human pregnancy: a link between the inflammasome and parturition. J Matern Fetal Neonatal Med: 2008; 21 605 616
87. Costa A., Gupta R., Signorino G., et al. Activation of the NLRP3 inflammasome by group B streptococci. J Immunol: 2012; 188 1953 1960
88. Eisenbarth S. C., Colegio O. R., O'Connor W., Sutterwala F. S., Flavell R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature: 2008; 453 1122 1126
89. Marichal T., Ohata K., Bedoret D., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med: 2011; 17 996 1002
90. Li H., Willingham S. B., Ting J. P., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol: 2008; 181 17 21
91. Lisciandro J. G., Prescott S. L., Nadal-Sims M. G., et al. Ontogeny of Toll-like and NOD-like receptor-mediated innate immune responses in Papua New Guinean infants. PLoS ONE: 2012; 7 e36793